Official Title: “Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost 0.005% to Preservative Free Tafluprost Eye Drops”

The purpose of this study is to investigate if changes in ocular signs and symptoms occur in patients with ocular hypertension or glaucoma when they switch from latanoprost 0.005% (Xalatan) to preservative free Tafluprost eye drops.

Study Type: Interventional

Study Design: Treatment, Open Label, Single Group Assignment

Study Primary Completion Date: June 2008

Intervention(s) in this Clinical Trial

• Drug: tafluprost
  • prostaglandine analoque

Arms, Groups and Cohorts in this Clinical Trial

• Other: 1 arm
  • Open-lable study with one arm.

Primary Measures

• Change from screening in ocular symptoms and signs
  • Time Frame: at week 6 and 12
    Safety Issue?: No

Secondary Measures

• Safety and Quality of life parameters.
  • Time Frame: From Screening (visit 1) to visits at week 2, 6 and 12.
    Safety Issue?: No

Inclusion Criteria:

• Patients with a diagnosis of ocular hypertension or open angle glaucoma for which the patient has been using latanoprost 0.005% as his/her prior medication. - Evaluable patients must have ocular surface related symptoms and/or signs with their prior medication.

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Sponsor: Santen Oy

Overall Clinical Trial Officials and Contacts

Hannu Uusitalo, Professor Principal Investigator Finn-Medi Research, Finland  

Overall Contact: Anneli Skinnari, Project Manager +358405811988 anneli.skinnari@santen.fi

Information obtained from ClinicalTrials.gov on September 05, 2008

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00596791

Study ID Number: Santen-77552

ClinicalTrials.gov Identifier: NCT00596791

Health Authority: Finland: National Agency for Medicines